and An outside, existential chance you win patent/IP disputes over Big Pharma to continue offering slightly different GLP-1s to consumers long-term (or some sort of other sustainable workaround)
Retatrutide targets three different receptors: GLP-1 (helps regulate appetite and blood sugar) GIP (supports insulin response) Glucagon (affects energy use and fat metabolism) By targeting all three, the medication delays how fast your stomach digests food, lowers your appetite, and ultimately reduces how much food you eat
Note: cases involving more than $25 million at stake typically reflect pharmaceutical patent disputes
Keeping a log of blood sugar readings can be helpful for adjusting medication dosages
This allows for better tolerance, steady progress, and more controlled results at every stage
Mounjaro targets two receptors and is already widely prescribed